Last reviewed · How we verify
Cisplatin/carboplatin plus etoposide
This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair.
This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair. Used for Small cell lung cancer, Germ cell tumors, Lymphomas.
At a glance
| Generic name | Cisplatin/carboplatin plus etoposide |
|---|---|
| Sponsor | EpicentRx, Inc. |
| Drug class | Combination chemotherapy |
| Target | DNA (platinum agents); Topoisomerase II (etoposide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin and carboplatin are alkylating agents that form covalent bonds with DNA, creating interstrand and intrastrand cross-links that prevent DNA replication and transcription, leading to cell death. Etoposide inhibits topoisomerase II, an enzyme essential for DNA unwinding, thereby trapping the enzyme on DNA and causing double-strand breaks. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Small cell lung cancer
- Germ cell tumors
- Lymphomas
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Nephrotoxicity (cisplatin)
- Ototoxicity (cisplatin)
- Peripheral neuropathy
- Alopecia
- Mucositis
- Secondary malignancy (etoposide)
Key clinical trials
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (PHASE3)
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer (PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin/carboplatin plus etoposide CI brief — competitive landscape report
- Cisplatin/carboplatin plus etoposide updates RSS · CI watch RSS
- EpicentRx, Inc. portfolio CI